Degludec Advisory Committee Is Another De Facto Delay For Novo
13:36 EDT 18 Jul 2012 | Elsevier Business Intelligence
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Original Article: Degludec Advisory Committee Is Another De Facto Delay For Novo
More From BioPortfolio on "Degludec Advisory Committee Is Another De Facto Delay For Novo"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
